This company is no longer active
HQ10 Stock Overview
A clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ARCA biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.85 |
| 52 Week High | US$3.94 |
| 52 Week Low | US$1.43 |
| Beta | 0.89 |
| 1 Month Change | -33.93% |
| 3 Month Change | -41.08% |
| 1 Year Change | -0.27% |
| 3 Year Change | -27.17% |
| 5 Year Change | -61.04% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| HQ10 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -45.6% | 0.4% | 0.4% |
| 1Y | -0.3% | -11.8% | 13.1% |
Return vs Industry: HQ10 exceeded the German Biotechs industry which returned -20.2% over the past year.
Return vs Market: HQ10 underperformed the German Market which returned 5% over the past year.
Price Volatility
| HQ10 volatility | |
|---|---|
| HQ10 Average Weekly Movement | 17.7% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: HQ10's share price has been volatile over the past 3 months.
Volatility Over Time: HQ10's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | Tom Keuer | www.arcabio.com |
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.
ARCA biopharma, Inc. Fundamentals Summary
| HQ10 fundamental statistics | |
|---|---|
| Market cap | €45.71m |
| Earnings (TTM) | -€6.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs HQ10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HQ10 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.20m |
| Earnings | -US$7.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HQ10 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/29 20:26 |
| End of Day Share Price | 2024/08/29 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ARCA biopharma, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Robert Wasserman | Dawson James Securities |
| Jason Napodano | Zacks Investment Research Inc. |